<DOC>
	<DOCNO>NCT01810705</DOCNO>
	<brief_summary>The protocol aim add GRASPA ( L-asparaginase encapsulate red blood cell ) standard chemotherapy ( low-dose cytarabine ) treat patient older 65 year diagnose AML unfit intensive chemotherapy . The investigator Assume 75 % improvement median Progression Free survival ( PFS ) L-asparaginase ( GRASPA ) plus low-dose cytarabine group compare median PFS low-dose cytarabine group ( control ) .</brief_summary>
	<brief_title>GRASPA Treatment Patients With Acute Myeloblastic Leukemia</brief_title>
	<detailed_description>L-asparaginase ( ASNase ) hold key role chemotherapy Acute Lymphoblastic Leukemia ( ALL ) child young adult . In elderly patient , efficacy counterbalance toxicity , impairs use . However , current study Red Blood Cells ( RBC ) encapsulate ASNase ( GRASPA® ) elderly ALL ( study reference `` GRASPALL-GRAAL SA2 2008 '' ) show efficacy/safety profile positive , pave way introduce ASNase benefit chemotherapy elderly patient . In adult , Capizzi ( 1988 ) report significant benefit ASNase associate high-dose cytarabine treatment ( HiDAC ) Acute Myeloid Leukemia ( AML ) . Indeed , overall statistically superior complete remission rate HiDAC/ASNase ( 40 % ) v HiDAC ( 24 % ) overall survival benefit patient treated HiDAC/ASNase ( 19.6 week vs 15.9 week . Another study elderly patient also display positive result ASNase treatment ( Petti , 1989 ) , well recent single case report point potential benefit ASNase different AML mixed lineage leukemia ( Horikoshi , 2009 ; Rubnitz , 2009 ) . Our preclinical result also show AML cell line blast cell bone marrow AML patient sensitive ASNase vitro . However , , toxicity ASNase elderly prevent use population represent majority AML patient . Aim Considering promising result ASNase AML treatment well safety profile offer RBC encapsulate ASNase ( GRASPA® ) , multicenter , randomize , control IIb trial open recruitment . Efficacy tolerability GRASPA® plus low-dose cytarabine evaluate versus low-dose cytarabine alone treatment AML patient 65 year-old , unfit intensive chemotherapy . One hundred twenty-three patient ( 65-85 year-old ) newly diagnose AML plan inclusion study . A 2:1 randomization respect ( 82 patient treat GRASPA® plus low-dose cytarabine 41 patient treat low-dose cytarabine alone ) . Each patient follow 24 month . Progression-free survival ( time elapse treatment initiation disease progression/death ) evaluate primary endpoint . A 75 % improvement median progression-free survival assume experimental group vs control group . Percentages remission ( complete partial ) , survival ( event-free overall ) , patient quality life , general safety , pharmacodynamic/pharmacokinetic immunogenicity GRASPA® also evaluate .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>Patient 65 year old less 85 year old Newly diagnose Acute Myeloid Leukemia post myelodysplastic syndrome diagnose 6 month prior study enrollment Unfit intensive chemotherapy ( risk suffer treatment related pejorative toxicity /early death ) patient unwilling receive intensive chemotherapy WHO performance status ≤2 estimate life expectancy ≥ 3 month Eligible receive lowdose cytarabine treatment Evidence postmenopausal status female ( absence menstruation 12 month ) Patients M3 AML French American British classification ( Acute Promyelocytic Leukemia ) Patients AML involve chromosome 16 abnormality translocation ( 8:21 ) History grade 34 pancreatitis grade 34 thromboembolic event Presenting general visceral contraindication ( Uncontrolled severe cardiovascular disease ; Plasma creatinine concentration 2 time great upper limit laboratory range ; Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) level , 3.5 time great upper limit laboratory range ; Patient present evolutive cancer AML , except situ basalcell carcinoma situ cervix cancer ; Severe evolutive infection , , HIV seropositive , active hepatitis relate B C viral infection ) History Grade 3 Transfusional incident Has know suspect hypersensitivity intolerance mannitol Patient present contra indication cytarabine treatment Participation investigational drug study within 30 day prior entry</criteria>
	<gender>All</gender>
	<minimum_age>65 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>myeloid</keyword>
	<keyword>leukemia</keyword>
</DOC>